Some CDMOs rigorously uphold the status quo. Others work from a mindset of relevant innovation. This paper identifies the essential characteristics of a CDMO willing to invest in new methods, approaches and novel technologies that can help ensure the success of your project.
More than 2,600 scientists and 7,000 employees provide the KNOW. Eight manufacturing facilities deliver the HOW. Asymchem is a single-source powerhouse for R&D and production across all stages of drug development. Our solutions range from early clinical stage to commercial stage, including R&D and cGMP production of advanced intermediates, APIs, formulations, as well as clinical research services. Driving our success is our commitment to continual optimization and investing in the future. By improving the capabilities our partners need now, and maintaining the agility needed to support innovation, we’ve built a knowledge and experience base that we’re ready to share.